Travoprost/timolol (Q36575744)

15 August 2017

1 reference

title

Travoprost/timolol (English)

1 reference

15 August 2017

3

Gillian M Keating

1 reference

15 August 2017

Sheridan M Hoy

1

1 reference

PubMed ID

16930087

15 August 2017

Susan J Keam

series ordinal

2

1 reference

15 August 2017

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

23

1 reference

15 August 2017

7

1 reference

15 August 2017

587-97; discussion 598-9

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200623070-00005

15 August 2017

0 references

cites work

Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002512-200623070-00005

The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002512-200623070-00005

The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol

21 January 2018

1 reference

12 December 2020

Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues

1 reference

12 December 2020

Management of glaucoma: focus on pharmacological therapy

1 reference

12 December 2020

In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells.

1 reference

12 December 2020

A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glauc

1 reference

12 December 2020

Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops

1 reference

12 December 2020

Pharmacological therapy for glaucoma: a review

1 reference

12 December 2020

Global data on visual impairment in the year 2002

1 reference

12 December 2020

Ocular Hypertension Treatment Study (OHTS) commentary

1 reference

12 December 2020

Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors

1 reference

12 December 2020

Efficacy and adverse effects of medications used in the treatment of glaucoma

1 reference

12 December 2020

In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells.

1 reference

12 December 2020

Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.

1 reference

12 December 2020

Diagnosis and management of open angle glaucoma: suggested guidelines for optometrists

1 reference

12 December 2020

A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution

1 reference

12 December 2020

Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor

1 reference

12 December 2020

10.2165/00002512-200623070-00005

Identifiers

DOI

1 reference

PubMed ID

16930087

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

16930087